Microbial L-asparaginase as a promising enzyme for treatment of various cancers

Area of Science:

• Biochemistry
• Enzymology
• Cancer Therapeutics

Background:

• Metabolic discrepancies between normal and cancerous cells are key targets for anticancer drug development.
• Amino acid-degrading enzymes, like L-Asparaginase (ASNase), demonstrate efficacy against specific cancer types.
• Bacterial ASNases from E. coli and E. chrysanthemi are FDA-approved for treating acute lymphoblastic leukemia (ALL).

Purpose of the Study:

• To review novel prokaryotic and eukaryotic sources of ASNases.
• To explore strategies for improving recombinant ASNase production and therapeutic properties.
• To discuss the application of ASNases in treating asparagine-auxotrophic cancers, including solid tumors.

Main Methods:

• Literature review of recent advancements in ASNase research.
• Analysis of strategies for chemical modification, immobilization, and nanoencapsulation of ASNases.
• Inclusion of in silico studies for optimizing enzyme efficiency and minimizing adverse effects.

Main Results:

• Identification of new natural sources for ASNase production.
• Advancements in recombinant ASNase engineering for enhanced stability and reduced toxicity.
• Emerging applications of ASNases beyond leukemia, particularly in solid cancers.

Conclusions:

• ASNase remains a potent therapeutic agent for asparagine-auxotrophic cancers.
• Ongoing research focuses on optimizing ASNase through various biotechnological approaches.
• Future directions include overcoming challenges to broaden ASNase applications and improve patient outcomes.